$ELOX
Eloxx Pharmaceuticals, Inc.

2012 Q4 Form 10-Q Financial Statement

#000114420412062352 Filed on November 14, 2012

View on sec.gov

Income Statement

Concept 2012 Q4 2012 Q3 2011 Q3
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $640.0K $670.0K $590.0K
YoY Change -23.81% 13.56% -7.81%
% of Gross Profit
Research & Development $591.1K $513.4K $634.2K
YoY Change -21.19% -19.04% -58.82%
% of Gross Profit
Depreciation & Amortization $70.00K $60.00K $60.00K
YoY Change 16.67% 0.0% 100.0%
% of Gross Profit
Operating Expenses $591.1K $513.4K $634.2K
YoY Change -64.39% -19.04% -71.3%
Operating Profit -$1.300M -$1.246M -$1.280M
YoY Change -2.66%
Interest Expense -$34.28K -$33.98K -$30.54K
YoY Change -51.03% 11.27% -110.18%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $0.00
YoY Change -100.0%
Pretax Income -$1.270M -$2.090M -$1.040M
YoY Change -16.99% 100.96% -48.51%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.270M -$2.085M -$1.039M
YoY Change -17.0% 100.72% -48.57%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$21.17M -$41.80M -$26.00M
COMMON SHARES
Basic Shares Outstanding 117.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2012 Q4 2012 Q3 2011 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $640.0K $1.310M $2.840M
YoY Change -58.71% -53.87% -54.85%
Cash & Equivalents $640.1K $1.312M $2.842M
Short-Term Investments
Other Short-Term Assets $1.300M $1.460M $1.820M
YoY Change -21.69% -19.78% 83.84%
Inventory
Prepaid Expenses $1.460M
Receivables
Other Receivables
Total Short-Term Assets $1.940M $2.772M $4.670M
YoY Change -39.56% -40.65% -35.85%
LONG-TERM ASSETS
Property, Plant & Equipment $10.00K $6.491K $0.00
YoY Change 0.0% -100.0%
Goodwill
YoY Change
Intangibles $3.477M
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K $10.00K $10.00K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $3.520M $3.488M $3.600M
YoY Change -3.56% -3.1% -23.08%
TOTAL ASSETS
Total Short-Term Assets $1.940M $2.772M $4.670M
Total Long-Term Assets $3.520M $3.488M $3.600M
Total Assets $5.460M $6.260M $8.270M
YoY Change -20.41% -24.3% -30.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.090M $932.2K $950.0K
YoY Change 147.73% -1.88% 93.88%
Accrued Expenses $470.0K $305.0K $650.0K
YoY Change -41.25% -53.08% -12.16%
Deferred Revenue
YoY Change
Short-Term Debt $2.200M $2.200M $2.200M
YoY Change 0.0% 0.0% 0.46%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.750M $3.436M $3.800M
YoY Change 8.7% -9.57% 10.47%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $130.0K $99.73K $540.0K
YoY Change -77.59% -81.53% -58.78%
Total Long-Term Liabilities $130.0K $99.73K $540.0K
YoY Change -77.59% -81.53% -58.78%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.750M $3.436M $3.800M
Total Long-Term Liabilities $130.0K $99.73K $540.0K
Total Liabilities $3.880M $3.631M $4.340M
YoY Change -3.48% -16.34% -8.63%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $1.168M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.580M $2.629M $3.930M
YoY Change
Total Liabilities & Shareholders Equity $5.460M $6.260M $8.270M
YoY Change -20.41% -24.3% -30.85%

Cashflow Statement

Concept 2012 Q4 2012 Q3 2011 Q3
OPERATING ACTIVITIES
Net Income -$1.270M -$2.085M -$1.039M
YoY Change -17.0% 100.72% -48.57%
Depreciation, Depletion And Amortization $70.00K $60.00K $60.00K
YoY Change 16.67% 0.0% 100.0%
Cash From Operating Activities -$560.0K -$636.5K -$1.090M
YoY Change -53.72% -41.62% -32.28%
INVESTING ACTIVITIES
Capital Expenditures -$100.0K $1.281K -$130.0K
YoY Change 0.0% -100.99% 0.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$100.0K -$147.0K -$128.8K
YoY Change 0.0% 14.09% -0.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 $94.18K 451.1K
YoY Change -100.0% -79.12%
NET CHANGE
Cash From Operating Activities -560.0K -$636.5K -1.090M
Cash From Investing Activities -100.0K -$147.0K -128.8K
Cash From Financing Activities 0.000 $94.18K 451.1K
Net Change In Cash -660.0K -$689.3K -768.0K
YoY Change -48.84% -10.25% -55.86%
FREE CASH FLOW
Cash From Operating Activities -$560.0K -$636.5K -$1.090M
Capital Expenditures -$100.0K $1.281K -$130.0K
Free Cash Flow -$460.0K -$637.7K -$960.2K
YoY Change -58.56% -33.59% -35.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2010Q1 us-gaap Line Of Credit Facility Interest Rate At Period End
LineOfCreditFacilityInterestRateAtPeriodEnd
0.0375 pure
CY2010Q1 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
3000000
CY2010Q1 snt Line Of Credit Spread Over Base Rate
LineOfCreditSpreadOverBaseRate
0.020 pure
CY2012Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
116975283 shares
CY2011Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
711259
CY2011Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3609954
CY2012Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
2199108
CY2012Q2 us-gaap Stockholders Equity
StockholdersEquity
3453028
CY2012Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2012Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
94112483 shares
CY2012Q2 us-gaap Line Of Credit Facility Amount Outstanding
LineOfCreditFacilityAmountOutstanding
2199108
CY2012Q2 us-gaap Liabilities
Liabilities
3501841
CY2012Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
594514
CY2012Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1548524
CY2012Q2 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
67440295
CY2012Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
99728
CY2012Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
238796
CY2012Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q2 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
CY2012Q2 us-gaap Assets
Assets
6954869
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.50
CY2012Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
5171
CY2012Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6954869
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2001325
CY2012Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
94112483 shares
CY2012Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3393992
CY2012Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
369695
CY2012Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3163317
CY2012Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
15647742 shares
CY2012Q2 us-gaap Common Stock Value
CommonStockValue
941125
CY2012Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q2 us-gaap Assets Current
AssetsCurrent
3549849
CY2012Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
238796
CY2012Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5857
CY2012Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
69952152
CY2011Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
21307814 shares
CY2011Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
439556
CY2011Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2841974
CY2011Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
439556
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
11588876 shares
CY2012Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
2199108
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
11777429 shares
CY2012Q3 us-gaap Stockholders Equity
StockholdersEquity
2629417
CY2012Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
864000
CY2012Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
6473
CY2012Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000 shares
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.57
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6473
CY2012Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
116753185 shares
CY2012Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
11620314 shares
CY2012Q3 us-gaap Line Of Credit Facility Amount Outstanding
LineOfCreditFacilityAmountOutstanding
2199108
CY2012Q3 us-gaap Liabilities
Liabilities
3630728
CY2012Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
932167
CY2012Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1459643
CY2012Q3 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
70149918
CY2012Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
99728
CY2012Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
94739
CY2012Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q3 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
CY2012Q3 us-gaap Assets
Assets
6260145
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.50
CY2012Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
5171
CY2012Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2012Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6260145
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1312056
CY2012Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
116753185 shares
CY2012Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3476784
CY2012Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
304986
CY2012Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3436261
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
15647742 shares
CY2012Q3 us-gaap Common Stock Value
CommonStockValue
1167532
CY2012Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2012Q3 us-gaap Assets Current
AssetsCurrent
2771699
CY2012Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
94739
CY2012Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6491
CY2012Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
71611793
CY2012Q3 snt Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber
3870313 shares
CY2012Q3 snt Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice
0.28
CY2012Q3 snt Shares Of Common Stock Issued In Exchange For Warrants
SharesOfCommonStockIssuedInExchangeForWarrants
3390625 shares
CY2010Q1 us-gaap Line Of Credit Facility Interest Rate Description
LineOfCreditFacilityInterestRateDescription
Line of Credit accrue at an annual interest rate of (i) the broker rate in effect at the interest date (which was 3.75% at September 30, 2012), plus (ii) 2.0%. There are no other conditions or fees associated with the Line of Credit.
us-gaap Costs And Expenses
CostsAndExpenses
54096435
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1147048
us-gaap Operating Income Loss
OperatingIncomeLoss
-52306435
us-gaap Revenue From Grants
RevenueFromGrants
244479
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
651781
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
932167
us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
5171
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
205390
us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
586442
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
2199108
us-gaap Share Based Compensation
ShareBasedCompensation
12259515
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
1909224
us-gaap Other Noncash Expense
OtherNoncashExpense
131250
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1163877
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37658844
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6556376
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1227869
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
185947
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1312056
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
32347397
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1459643
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
11227870
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
2160986
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21749038
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
45527276
us-gaap Interest Expense Debt
InterestExpenseDebt
2027930
us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
115869
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
250006
us-gaap Noncash Contribution Expense
NoncashContributionExpense
85179
us-gaap Paid In Kind Interest
PaidInKindInterest
2003386
us-gaap Revenues
Revenues
1790000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
356924
us-gaap Interest Paid
InterestPaid
406673
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
6370429
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
10000000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
11127710
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
25421366
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
53800
us-gaap Net Income Loss
NetIncomeLoss
-59022208
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-70149918
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
8631241
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
430235
us-gaap Increase Decrease In Fair Value Of Unhedged Derivative Instruments
IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments
8309982
snt Proceeds From Government Grant
ProceedsFromGovernmentGrant
99728
snt Preferred Dividends Accrued Not Yet Paid
PreferredDividendsAccruedNotYetPaid
49752
snt Proceeds From Issuance Of Preferred Stock And Warrants Net
ProceedsFromIssuanceOfPreferredStockAndWarrantsNet
10754841
snt Warrants Issued For Financing Costs
WarrantsIssuedForFinancingCosts
690984
CY2011Q3 us-gaap Costs And Expenses
CostsAndExpenses
1280145
CY2011Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
pure
CY2011Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1280145
CY2011Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
389565
CY2011Q3 us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
-7187
CY2011Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.010 pure
CY2011Q3 us-gaap Share Based Compensation
ShareBasedCompensation
123551
CY2011Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
CY2011Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2011Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
57319
CY2011Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1090238
CY2011Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-128839
CY2011Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-767980
CY2011Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.02 pure
CY2011Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
645959
CY2011Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
378455
CY2011Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-271703
CY2011Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
634186
CY2011Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
451097
CY2011Q3 us-gaap Interest Expense Short Term Borrowings
InterestExpenseShortTermBorrowings
33310
CY2011Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.05 pure
CY2011Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-30541
CY2011Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
pure
CY2011Q3 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
1555
CY2011Q3 us-gaap Interest Paid
InterestPaid
33310
CY2011Q3 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
128839
CY2011Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
79289756 shares
CY2011Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
908846
CY2011Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.019 pure
CY2011Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
88806984 shares
CY2011Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
451097
CY2011Q3 us-gaap Net Income Loss
NetIncomeLoss
-1038983
CY2011Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
4213000 shares
CY2011Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1947829
CY2011Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
271703
CY2011Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
21281
CY2011Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.18
CY2011Q3 us-gaap Increase Decrease In Fair Value Of Unhedged Derivative Instruments
IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments
271703
CY2011Q3 snt Preferred Dividends Accrued Not Yet Paid
PreferredDividendsAccruedNotYetPaid
119998
CY2011Q3 snt Class Of Warrant Or Right Grants In Period
ClassOfWarrantOrRightGrantsInPeriod
shares
CY2012Q3 dei Trading Symbol
TradingSymbol
SNT
CY2012Q3 dei Entity Registrant Name
EntityRegistrantName
SENESCO TECHNOLOGIES INC
CY2012Q3 dei Amendment Flag
AmendmentFlag
false
CY2012Q3 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2012Q3 us-gaap Share Based Compensation
ShareBasedCompensation
153562
CY2012Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
CY2012Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
pure
CY2012Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-785171
CY2012Q3 us-gaap Basis Of Accounting
BasisOfAccounting
<div style="FONT: 10pt Times New Roman, Times, Serif"> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>Note 1 - Basis of Presentation:</b></p> <p style="TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#xA0;</p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The financial statements included herein have been prepared by Senesco Technologies, Inc. (the &#x201C;Company&#x201D;), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with United States generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended June 30, 2012, as amended.</p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#xA0;</p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> In the opinion of the Company&#x2019;s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting solely of those which are of a normal recurring nature, necessary to present fairly its financial position as of September 30, 2012, the results of its operations and cash flows for the three months ended September 30, 2012 and 2011.</p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> &#xA0;</p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Interim results are not necessarily indicative of results for the full fiscal year.</p> </div>
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1246153
CY2012Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
337653
CY2012Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
CY2012Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2012Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2012Q3 dei Document Type
DocumentType
10-Q
CY2012Q3 dei Document Period End Date
DocumentPeriodEndDate
2012-09-30
CY2012Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001035354
CY2012Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2012Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
-164205
CY2012Q3 us-gaap Costs And Expenses
CostsAndExpenses
1246153
CY2012Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y
CY2012Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
63572
CY2012Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-636454
CY2012Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-146998
CY2012Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2012Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
100570
CY2012Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1281
CY2012Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-689269
CY2012Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
732720
CY2012Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-88881
CY2012Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P36M
CY2012Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
20148
CY2012Q3 us-gaap Stock Issued During Period Value Stock Dividend
StockIssuedDuringPeriodValueStockDividend
114474
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
513433
CY2012Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
94183
CY2012Q3 us-gaap Interest Expense Short Term Borrowings
InterestExpenseShortTermBorrowings
34990
CY2012Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-33982
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
pure
CY2012Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y8M12D
CY2012Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
153562
CY2012Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M18D
CY2012Q3 us-gaap Dividends
Dividends
49752
CY2012Q3 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
137810
CY2012Q3 us-gaap Interest Paid
InterestPaid
34990
CY2012Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
6387
CY2012Q3 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
145717
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
107449311 shares
CY2012Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
624169
CY2012Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
59571479 shares
CY2012Q3 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
94183
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-2085454
CY2012Q3 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P17Y
CY2012Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
shares
CY2012Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2709623
CY2012Q3 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
0.26
CY2012Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-20148
CY2012Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
13
CY2012Q3 us-gaap Increase Decrease In Fair Value Of Unhedged Derivative Instruments
IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments
-20148
CY2012Q3 snt Preferred Dividends Accrued Not Yet Paid
PreferredDividendsAccruedNotYetPaid
-64722
CY2012Q3 snt Deemed Dividends On Preferred Stock
DeemedDividendsOnPreferredStock
240891
CY2012Q3 snt Reclassification Of Warrant Liabilities To Equity
ReclassificationOfWarrantLiabilitiesToEquity
164205
CY2012Q3 snt Number Of Warrants Exchanged
NumberOfWarrantsExchanged
9687500 shares
CY2012Q3 snt Class Of Warrant Or Right Grants In Period
ClassOfWarrantOrRightGrantsInPeriod
shares
CY2012Q3 snt Warrant Liability Estimated Likelihood Of Reset Percentage
WarrantLiabilityEstimatedLikelihoodOfResetPercentage
0.75 pure

Files In Submission

Name View Source Status
0001144204-12-062352-index-headers.html Edgar Link pending
0001144204-12-062352-index.html Edgar Link pending
0001144204-12-062352.txt Edgar Link pending
0001144204-12-062352-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snt-20120930.xml Edgar Link completed
snt-20120930.xsd Edgar Link pending
snt-20120930_cal.xml Edgar Link unprocessable
snt-20120930_def.xml Edgar Link unprocessable
snt-20120930_lab.xml Edgar Link unprocessable
snt-20120930_pre.xml Edgar Link unprocessable
v325920_10q.htm Edgar Link pending
v325920_ex31-1.htm Edgar Link pending
v325920_ex31-2.htm Edgar Link pending
v325920_ex32-1.htm Edgar Link pending
v325920_ex32-2.htm Edgar Link pending